Novel Corona virus (COVID-19)
Corona contagions are positive sense single stranded RNA contagions that beget infection in nose, sinuses, or upper throat. It belongs to family of SARS and MERS. COVID-19 is the illness caused by SARS-COV-2, first outbreak does Wuhan megacity in China.
The pathogenesis of COVID-19 isn't defined but reports from numerous countries indicate that the contagion has the same medium by which it enters or invades host cells as SARS-COV. The origin of SARS-CoV-2 isn't well- established, still, it's established that batons are the fountainhead of affiliated contagions and that mortal to mortal transmission plays a critical part in its pathogenesis After entering into target cells following Shaft protein association with its receptor, viral RNA is reprised and polyadenylated, and encodes colorful structural andnon-structural polypeptide genes.
These polyproteins are adhered by proteases that parade chymotrypsin-suchlike exertion. Although transmembrane serine protease 2 (TMPRSS2) is the major protease associated with CoV activation and has been linked to SARS-CoV-2 activation, recent substantiation from single cell RNA-sequencing (scRNA-seq) analysis shows that ACE2 and TMPRSS2 aren't expressed in the same cell suggesting the involvement of other proteases similar as cathepsin B and L in this process.
In general, pattern recognition receptors (PRRs) fete overrunning pathogens including contagion’s. Contagions evoke several crucial host vulnerable responses similar as adding the release of seditious factors, induction and development of dendritic cells (DCs) and adding the conflation of type I interferons (IFNs), which are important in limiting viral spread. Both the ingrain and acquired vulnerable response is actuated by SARS-CoV-2. CD4 T cells stimulate B cells to produce contagion-specific antibodies including immunoglobulin (Ig) G and IgM and CD8 T cells directly kill contagion-infected cells. T coadjutor cells producer-inflammatory cytokines and intercessors to help the other vulnerable cells. SARS-CoV-2 can block the host vulnerable defense by suppressing T cell functions by converting their programmed cell deathe.g., by apoptosis. Likewise, the host product of complement factors similar as C3a and C5a and antibodies are critical in combating the viral infection.
Related Conference of Novel Corona virus (COVID-19)
5th International conference on Vaccines, Vaccination and Immunization
19th International Conference on Allergy and Clinical Immunology
5th International Conference on Immunology And Immunotherapy
Novel Corona virus (COVID-19) Conference Speakers
Recommended Sessions
- Diagnostic Immunology
- Haematopoietic, Lymphoid Malignancies and Immune System Development
- Immune System and Immunology
- Immunization and Vaccination
- Veterinary Allergology
- Allergy and Immunology
- Autoimmune Diseases and HIV
- Immune Disorder
- Immune Response Regulation
- Immunogenetics
- Immunoresearch and Immunotechnology
- Microbial Parasitic and Fungal Immunology
- Mucosal and regional Immunology
- Neonatal and Pediatric Immunology
- NeuroImmunology
- Novel Corona virus (COVID-19)
- OncoImmunology
- Stem Cells Immunology
- Technological Innovations in Immunology
- Therapeutic approaches to autoimmunity
- Thyroid Autoimmunity
- Transplantation and Computational Immunology
- Vaccines and Immunotherapy
- Veterinary and Comparative Immunology
- Viral Immunology
Related Journals
Are you interested in
- Advances in Molecular Immunology - ALLERGY 2024 (France)
- Allergen Identification and Characterization - ALLERGY 2024 (France)
- Biomarkers for Allergy Diagnosis and Treatment - ALLERGY 2024 (France)
- Case Studies in Allergy Diagnosis and Management - ALLERGY 2024 (France)
- Clinical Trials and Translational Research in Allergy and Immunology - ALLERGY 2024 (France)
- Digital Health and Telemedicine in Allergy Care - ALLERGY 2024 (France)
- Epidemiology and Population Studies in Allergic Diseases - ALLERGY 2024 (France)
- Immune Responses to Vaccination - ALLERGY 2024 (France)
- Immunogenetics and Allergic Susceptibility - ALLERGY 2024 (France)
- Immunological Aspects of Drug Allergies - ALLERGY 2024 (France)
- Immunological Basis of Food Allergy - ALLERGY 2024 (France)
- Immunological Mechanisms in Autoimmune Diseases - ALLERGY 2024 (France)
- Immunomodulation in Allergy Management - ALLERGY 2024 (France)
- Immunopathogenesis of Allergic Diseases - ALLERGY 2024 (France)
- Immunotherapy for Allergic Conditions - ALLERGY 2024 (France)
- Inflammatory Pathways in Asthma and Allergic Rhinitis - ALLERGY 2024 (France)
- Mechanisms of Immunodeficiency Diseases - ALLERGY 2024 (France)
- Novel Therapeutic Approaches for Allergic Disorders - ALLERGY 2024 (France)
- Role of Microbiota in Allergic Disorders - ALLERGY 2024 (France)